Roivant to buy Silicon Therapeutics for $450 million to boost drug discovery
(Reuters) - Roivant Sciences said on Friday it will buy drug developer Silicon Therapeutics for $450 million in an equity deal to strengthen its artificial intelligence capabilities for drug discovery.
